KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2025)

Historic Raw Materials for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Q3 2025 value amounting to $77.8 million.

  • Acadia Pharmaceuticals' Raw Materials rose 8441.37% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.8 million, marking a year-over-year increase of 8441.37%. This contributed to the annual value of $69.7 million for FY2024, which is 12272.93% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Raw Materials is $77.8 million, which was up 8441.37% from $83.7 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Raw Materials high stood at $83.7 million for Q2 2025, and its period low was $1.5 million during Q2 2021.
  • In the last 5 years, Acadia Pharmaceuticals' Raw Materials had a median value of $6.8 million in 2023 and averaged $29.8 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Raw Materials tumbled by 4382.52% in 2021 and then skyrocketed by 93436.41% in 2024.
  • Acadia Pharmaceuticals' Raw Materials (Quarter) stood at $6.2 million in 2021, then fell by 16.25% to $5.2 million in 2022, then surged by 501.34% to $31.3 million in 2023, then skyrocketed by 122.73% to $69.7 million in 2024, then grew by 11.53% to $77.8 million in 2025.
  • Its Raw Materials was $77.8 million in Q3 2025, compared to $83.7 million in Q2 2025 and $76.5 million in Q1 2025.